Certara and Veristat Expand Clinical Trial Service Offerings
News May 15, 2013
Certara™ and Veristat, LLC. announced that they have formed an alliance to offer combined services to their clients. The joint service offering includes: Pharmacokinetic (PK) analysis, PK /Pharmacodynamic (PD) modeling, population PK modeling, trial simulation, clinical biostatistics, medical writing, data management, clinical monitoring, safety management, and project management. These combined services will help streamline the drug discovery, development and trial planning processes by improving the efficiency of data collection and analysis and enabling clients to procure value-added services through their existing vendor relationship.
“We look forward to offering Certara’s capabilities to our clients”
“We look forward to offering Certara’s capabilities to our clients,” said Patrick Flanagan, Chief Business Officer of Veristat. “Their Pharsight Consulting Services team is a world-class organization in the modeling and simulation of drugs and diseases. By combining our core services with their insight and experience, Veristat broadens our delivery platform and is able to more immediately respond to our clients’ outsourcing needs. The benefit to our clients is greater overall efficiency, impact and probability of success for their clinical trial programs.”
“We are pleased to partner with Veristat to expand what we can offer to clients as they seek to streamline their outsourcing of critical tasks in trial planning, analysis, and reporting,” said Daniel Weiner, Chief Technology Officer and head of Certara’s scientific consulting services. “Veristat specializes in several trial services that lie outside our core domain, and together we can offer more to the client than either organization could alone.”
Pre-Clinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”News
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients.
Dr Richard Knight of ApconiX will tell this month’s conference, that greater focus on pre-clinical safety should be fundamental to the development of new cancer therapies.
Researchers Test Drug Transfer Using Placenta-On-A-ChipNews
Researchers have demonstrated the feasibility of their "organ-on-a-chip" platform in studying how drugs are transported across the human placental barrier.READ MORE
'Click Chemistry' Reactions Could Boost Cancer-Fighting Drug PotencyNews
Researchers at The Scripps Research Institute (TSRI) have developed a quick and easy way to simultaneously modify dozens of drugs or molecules to improve their disease-fighting properties.READ MORE
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018